Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes dietary supplement and beauty products.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.023|
|52 Week High||AU$0.01|
|52 Week Low||AU$0.035|
|1 Month Change||-17.86%|
|3 Month Change||-23.33%|
|1 Year Change||91.67%|
|3 Year Change||-39.47%|
|5 Year Change||15.01%|
|Change since IPO||-87.90%|
Recent News & Updates
|BXN||AU Personal Products||AU Market|
Return vs Industry: BXN exceeded the Australian Personal Products industry which returned 15.6% over the past year.
Return vs Market: BXN exceeded the Australian Market which returned 19.3% over the past year.
Stable Share Price: BXN is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: BXN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes dietary supplement and beauty products. The company operates in two segments, Wholesale Sales and Direct Sales. It engages in developing a range of functional foods and beauty products.
Bioxyne Fundamentals Summary
|BXN fundamental statistics|
Is BXN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BXN income statement (TTM)|
|Cost of Revenue||AU$1.03m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.00077|
|Net Profit Margin||-22.49%|
How did BXN perform over the long term?See historical performance and comparison
Is Bioxyne undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: BXN (A$0.02) is trading above our estimate of fair value (A$0)
Significantly Below Fair Value: BXN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BXN is unprofitable, so we can't compare its PE Ratio to the Global Personal Products industry average.
PE vs Market: BXN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BXN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BXN is overvalued based on its PB Ratio (7.8x) compared to the AU Personal Products industry average (3x).
How is Bioxyne forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioxyne has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bioxyne performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BXN is currently unprofitable.
Growing Profit Margin: BXN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BXN is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare BXN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BXN is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (23%).
Return on Equity
High ROE: BXN has a negative Return on Equity (-25.63%), as it is currently unprofitable.
How is Bioxyne's financial position?
Financial Position Analysis
Short Term Liabilities: BXN's short term assets (A$2.5M) exceed its short term liabilities (A$744.7K).
Long Term Liabilities: BXN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: BXN is debt free.
Reducing Debt: BXN has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BXN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BXN is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 9.4% per year.
What is Bioxyne current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BXN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BXN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BXN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BXN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BXN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Nam Hoat Chua, BA, has been the Chief Executive Officer and Managing Director of Bioxyne Limited since June 13, 2017. Mr. Chua served as Vice President of Asia Operations of New Image Group Limited for...
CEO Compensation Analysis
Compensation vs Market: Nam's total compensation ($USD107.09K) is below average for companies of similar size in the Australian market ($USD300.24K).
Compensation vs Earnings: Nam's compensation has been consistent with company performance over the past year.
Experienced Board: BXN's board of directors are considered experienced (6.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bioxyne Limited's employee growth, exchange listings and data sources
- Name: Bioxyne Limited
- Ticker: BXN
- Exchange: ASX
- Founded: 1998
- Industry: Personal Products
- Sector: Household
- Market Cap: AU$14.723m
- Shares outstanding: 640.15m
- Website: https://www.bioxyne.com
- Bioxyne Limited
- 50 Clarence Street
- Suite 506
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 15:49|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.